SZSE:300039 (China)
Â
Class A
Â¥
6.48
(+1.73%)
Dec 27
Business Description
Shanghai Kaibao Pharmaceutical Co Ltd
NAICS : 325411
SIC : 2833
ISIN : CNE100000JZ3
Share Class Description:
SZSE:300039: Class ACompare
Compare
Traded in other countries / regions
300039.China IPO Date
2010-01-08Description
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 442.65 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 2369.95 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 10.36 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.6 | |||||
| 3-Year EBITDA Growth Rate | 28.6 | |||||
| 3-Year EPS without NRI Growth Rate | 44.6 | |||||
| 3-Year FCF Growth Rate | 14.4 | |||||
| 3-Year Book Growth Rate | 16.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.09 | |||||
| 9-Day RSI | 42.09 | |||||
| 14-Day RSI | 44.73 | |||||
| 6-1 Month Momentum % | 24.39 | |||||
| 12-1 Month Momentum % | 1.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.36 | |||||
| Quick Ratio | 5.77 | |||||
| Cash Ratio | 4.18 | |||||
| Days Inventory | 217.16 | |||||
| Days Sales Outstanding | 75.28 | |||||
| Days Payable | 232.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.54 | |||||
| Dividend Payout Ratio | 0.29 | |||||
| 3-Year Dividend Growth Rate | -15.7 | |||||
| Forward Dividend Yield % | 1.54 | |||||
| 5-Year Yield-on-Cost % | 0.67 | |||||
| Shareholder Yield % | 1.54 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.97 | |||||
| Operating Margin % | 22.32 | |||||
| Net Margin % | 22.35 | |||||
| FCF Margin % | 12.93 | |||||
| ROE % | 9.18 | |||||
| ROA % | 8.09 | |||||
| ROIC % | 9.75 | |||||
| ROC (Joel Greenblatt) % | 81.39 | |||||
| ROCE % | 9.71 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.4 | |||||
| PE Ratio without NRI | 18.95 | |||||
| Shiller PE Ratio | 26.13 | |||||
| Price-to-Owner-Earnings | 22.42 | |||||
| PS Ratio | 4.34 | |||||
| PB Ratio | 1.76 | |||||
| Price-to-Tangible-Book | 1.84 | |||||
| Price-to-Free-Cash-Flow | 33.58 | |||||
| Price-to-Operating-Cash-Flow | 19.23 | |||||
| EV-to-EBIT | 14.18 | |||||
| EV-to-EBITDA | 14.18 | |||||
| EV-to-Revenue | 3.5 | |||||
| EV-to-FCF | 27.05 | |||||
| Price-to-Projected-FCF | 1.11 | |||||
| Price-to-Median-PS-Value | 0.84 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.97 | |||||
| Price-to-Graham-Number | 1.25 | |||||
| Price-to-Net-Current-Asset-Value | 4.41 | |||||
| Price-to-Net-Cash | 8 | |||||
| Earnings Yield (Greenblatt) % | 7.05 | |||||
| FCF Yield % | 2.98 | |||||
| Forward Rate of Return (Yacktman) % | 13.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Kaibao Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,560.961 | ||
| EPS (TTM) (Â¥) | 0.334 | ||
| Beta | 1.09 | ||
| Volatility % | 30.04 | ||
| 14-Day RSI | 44.73 | ||
| 14-Day ATR (Â¥) | 0.188727 | ||
| 20-Day SMA (Â¥) | 6.688 | ||
| 12-1 Month Momentum % | 1.22 | ||
| 52-Week Range (Â¥) | 4.9 - 7.6 | ||
| Shares Outstanding (Mil) | 1,046 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Kaibao Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Kaibao Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Kaibao Pharmaceutical Co Ltd Frequently Asked Questions
What is Shanghai Kaibao Pharmaceutical Co Ltd(SZSE:300039)'s stock price today?
The current price of SZSE:300039 is ¥6.48. The 52 week high of SZSE:300039 is ¥7.60 and 52 week low is ¥4.90.
When is next earnings date of Shanghai Kaibao Pharmaceutical Co Ltd(SZSE:300039)?
The next earnings date of Shanghai Kaibao Pharmaceutical Co Ltd(SZSE:300039) is .
Does Shanghai Kaibao Pharmaceutical Co Ltd(SZSE:300039) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Kaibao Pharmaceutical Co Ltd(SZSE:300039) is 1.54% (As of Today), Highest Dividend Payout Ratio of Shanghai Kaibao Pharmaceutical Co Ltd(SZSE:300039) was 1.09. The lowest was 0.22. And the median was 0.42. The  Forward Dividend Yield % of Shanghai Kaibao Pharmaceutical Co Ltd(SZSE:300039) is 1.54%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers